Douglass Winthrop Advisors, LLC Novo Nordisk A S Transaction History

Douglass Winthrop Advisors, LLC

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 07, 2024	SELL	$122.71 - $146.91 $3,681 - $4,407	-30 Reduced 1.87%	1,576 $224,000
Q1 2024 May 13, 2024	BUY	$102.11 - $135.92 $163,988 - $218,287	1,606 New	1,606 $206,000
Q3 2018 Oct 12, 2018	SELL	$46.76 - $51.24 $668,668 - $732,732	-14,300 Closed	0 $0
Q2 2018 Jul 24, 2018	SELL	$44.29 - $50.42 $57,577 - $65,546	-1,300 Reduced 8.33%	14,300 $660,000
Q1 2018 May 08, 2018	SELL	$48.49 - $58.14 $57,606 - $69,070	-1,188 Reduced 7.08%	15,600 $768,000
Q4 2017 Feb 13, 2018	SELL	$47.53 - $53.73 $133,654 - $151,088	-2,812 Reduced 14.35%	16,788 $901,000
Q3 2017 Nov 13, 2017	BUY	$41.15 - $49.22 $806,540 - $964,712	19,600	19,600 $0

1,957

320M

5.49M

7.78M

Ticker NVO
Exchange OTC
Sector Healthcare
Industry Biotechnology
Shares Outstandng 2,257,289,984
Market Cap $197B
Description
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabeti...

Get notified when there are updates to the investment portfolio of Douglass Winthrop Advisors, LLC, based on Form 13F filings with the SEC.

Stay updated on Douglass Winthrop Advisors, LLC with notifications on news.